WNT3A and colorectal carcinoma: These data were confirmed in patient-derived CRC-SCs treated with Wnt3a and/or ralimetinib and/or the Wnt pathway inhibitor PRI-724, and suggest that p38α is involved in the activation of β-catenin target gene transcription in CRC cells and patient-derived CRC-SC tumorspheres (Fig. 4E).